Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Prospective Study Assessing the Relationship Between Expression of the Norepinephrine Transporter and 18F-mFBG PET Imaging Results in Neuroblastoma Tumor, Other Neural Crest Tumors, and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to:
compare the findings against other catacholamine transporters
evaluate the imaging results at different time points and in different organs
assess the quality of images with lower doses
compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors
An Open-Label, Exploratory, Phase 1/2 Scintigraphy Study Evaluating 18F-mFBG for Imaging Myocardial Sympathetic Innervation in Subjects Without and With Heart Disease
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
100 Clinical Results associated with Illumina Radiopharmaceuticals LLC
0 Patents (Medical) associated with Illumina Radiopharmaceuticals LLC
100 Deals associated with Illumina Radiopharmaceuticals LLC
100 Translational Medicine associated with Illumina Radiopharmaceuticals LLC